.2018 .. , 05(12) : 1169-75.
Salah RB,Kacem FH,Soomauro S,Chouaib S,Frikha F,Charfi N . .Autoimmune thyroiditis associated with autoimmune 3. , : .
Ek M,Roth B,Nilsson PM,Ohlsson B .2018 .Characteristics of endometriosis: A case-cohort study showing elevated IgG titers against the TSH receptor (TRAb) and mental comorbidity. Eur J Obstet Gynecol Reprod Biol, 09 : 8.
Neag E,Smith T. 2021 .2022 .update on thyroid-associated ophthalmopathy. J Endocrinol Invest, 45(2) : 235-59.
. .. [PubMed] DOI: 10.1007/s40618-021-01663-9, : .
Marín-Sánchez A,Álvarez-Sierra D,González O,Lucas-Martin A,Sellés-Sánchez A,Rudilla F .2019 .Regulation of TSHR expression in the thyroid and thymus may contribute to TSHR tolerance failure in Grave's disease patients via two distinct mechanisms. Front Immunol, 10 : 1695.
Khan MS,Lone SS,Faiz S,Farooq I,Majid S .2021 .Disease: Pathophysiology, Genetics and Management. , 10 : .
Antonelli A,Fallahi P,Rotondi M,Ferrari SM,Romagnani P,Grosso M . .Increased serum CXCL10 in Grave's disease or autoimmune thyroiditis is not associated with hyper-or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol., : .
.2006 .. , 154(5) : 02137-8.
Pokhrel B,Bhusal K. Graves,Disease K. Graves .2024 .. , : .
Antonelli A,Fallahi P,Elia G,Ragusa F,Paparo SR,Ruffilli I .2020 .Grave's disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Pract Res Clin Endocrinol Metab, 34(1) : 101388.
Mace ML,Olgaard K,Lewin E .2020 .New aspects of the kidney in the regulation of fibroblast growth factor 23 (FGF23) and mineral homeostasis. Int J Mol Sci, 21(22) : 8810.
Erben RG .2018 .. Physiological actions of fibroblast growth factor-23. Front Endocrinol, 267 : .
Agoro R,Ni P,Noonan ML,White KE .2020 .Osteocytic FGF23 and its kidney function. Front Endocrinol, 11 : 592.
Rayego-Mateos S,Doladé N,García-Carrasco A,Diaz-Tocados JM,Ibarz M,Valdivielso JM .2022 .The increase in FGF23 induced by calcium is partially dependent on vitamin D signaling. , 14(13) : 2576.
Goltzman D,Feingold KR,Anawalt B,Blackman MR .2000 .. , : .
Lin CH,Chang CK,Shih CW,Li HY,Chen KY,Yang WS .2019 .Serum fibroblast growth factor 23 and mineral metabolism in patients with euthyroid Grave's diseases: A case-control study. Osteoporos Int, 30(11) : 2289-97.
Huang C-L,Moe OW .2021 .Soluble α-klotho-a fibroblast growth factor 23-independent hormone. Fibroblast Growth Factor, 23 : 233-40.
Hanson K,Fisher K,Hooper NM .2021 .Exploiting the neuroprotective effects of α-klotho to tackle ageing-and neurodegenerationrelated cognitive dysfunction. Neuronal Signal, 5(2) : .
Bellido T,Pajevic PD,Bonewald L. Osteocyte,Biology L. Osteocyte . .. Genetics of Bone Biology and Skeletal Disease: Elsevier; 2018, : 227-40.
Wang W,Su Y,Xu J,Yao W,Qin Q,He S .2018 .Elevated serum concentrations of FGF23 and Klotho in patients with Grave's disease and their significance. Clin Med China, 06 : 6315-4.
Kuro-o M. .2013 .Klotho, phosphate and FGF23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol, 9(11) : 650-60.
Yuan Q,Shen F,Chen B .2018 .FGF23 as a new biomarker for differentiating Graves' disease and Hashimoto's thyroiditis. J Endocrinol Invest, 41(2) : 149-57.
Kadooh QA,Al-Ziaydi AG,Hamza AJ .2024 .Evaluation of the influence of trastuzumab therapy on serum levels of HER-2 protein and breast cancer cell lines. Menopause Rev, 10(2) : 57-63.